Role of the NF-κB axis in immune modulation of osteoclasts and bone loss

References

• Goldring SR. Bone and joint destruction in rheumatoid arthritis: What is really happening?. J Rheumatol Suppl 2002; 65: 44–48
   PubMedGoogle Scholar
• Gravallese EM. Bone destruction in arthritis. Ann Rheum Dis 2002; 61: 84ii–86
   Google Scholar
• Romas E, Bakharevski O, Hards D, Kartsogiannis V, Quinn M, Ryan P, Martin T, Gillespie MT. Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum 2000; 43: 821–826
   PubMed Web of Science ®Google Scholar
• Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, Koshihara Y, Oda H, Nakamura K, Tanaka S. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000; 43: 259–269
   PubMed Web of Science ®Google Scholar
• Teitelbaum S. Bone resorption by osteoclasts. Science 2000; 289: 1504–1508
   PubMed Web of Science ®Google Scholar
• Wong BR, Besser D, Kim N, Arron JR, Vologodskaia M, Hanafusa H, Choi Y. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell 1999; 4: 1041–1049
   PubMed Web of Science ®Google Scholar
• Sato K, Takayanagi H. Osteoclasts, rheumatoid arthritis and osteoimmunology. Curr Opin Rheumatol 2006; 18: 419–426
   PubMed Web of Science ®Google Scholar
• Takayanagi H. Mechanistic insight into osteoclast differentiation in osteoimmunology. J Mol Med 2005; 83: 170–179
   PubMed Web of Science ®Google Scholar
• Takayanagi H, Sato K, Takaoka A, Taniguchi T. Interplay between interferon and other cytokine systems in bone metabolism. Immunol Rev 2005; 208: 181–193
   PubMedGoogle Scholar
• Walsh MC, Kim N, Kadono Y, Rho J, Lee SY, Lorenzo J, Choi Y. Osteoimmunology: Interplay between the immune system and bone metabolism. Annu Rev Immunol 2006; 24: 33–63
   PubMed Web of Science ®Google Scholar
• Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, Tanaka S, Kodama T, Akira S, Iwakura Y, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006; 203: 2673–2682
   PubMed Web of Science ®Google Scholar
• Abu-Amer Y, Tondravi MM. NFkB and bone: The breaking point. Nat Med 1997; 3: 1189–1190
   PubMedGoogle Scholar
• Baldwin AS, Jr. The NF-kB and IkB proteins: New discoveries and insights. Annu Rev Immunol 1996; 14: 649–683, [Review] [180 refs]
   PubMed Web of Science ®Google Scholar
• Tak P, Firestein G. NF-kB: A key role in inflammatory diseases. J Clin Invest 2001; 107: 7–11
   PubMed Web of Science ®Google Scholar
• Iotsova V, Caamano J, Loy J, Young Y, Lewin A, Bravo R. Osteopetrosis in mice lacking NFkB1 and NFkB2. Nat Med 1997; 3: 1285–1289
   PubMed Web of Science ®Google Scholar
• Baldwin A. The transcription factor NF-kB and human disease. J Clin Invest 2001; 107: 3–6
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Gaynor R. Therapeutic potential of inhibition of the NF-kB pathway in the treatment of inflammation and cancer. J Clin Invest 2001; 107: 135–142
   PubMed Web of Science ®Google Scholar
• Boyce B, Xing L, Fransozo G, Siebenlist U. Required and nonessential functions of nuclear factor-kB in bone cells. Bone 1999; 25: 137–139
   PubMed Web of Science ®Google Scholar
• Siebenlist U, Franzoso G. Structure, regulation and function of NF-kB. Proc Natl Acad Sci USA 2001; 89: 4333–4337
   Google Scholar
• Abu-Amer Y, Faccio R. Therapeutic approaches in bone pathogeneses: Targeting the IKK/NF-κB axis. Future Rheumatol 2006; 1: 133–146
   Google Scholar
• Ghosh S, Karin M. Missing pieces in the NF-kB puzzle. Cell 2002; 109: S81–S96
   PubMed Web of Science ®Google Scholar
• Karin M, Yamamoto Y, Wang M. The IKK NF-kB system: A treasure trove for drug development. Nat Rev 2004; 3: 17–26
   Google Scholar
• Franzoso G, Carlson L, Poljak L, Shores E, Brown K, Leonardi A, Tran T, Boyce B, Siebenlist U. Requirment for NF-kB in osteoclast and B-cell development. Genes Dev 1997; 11: 3482–3496
   PubMed Web of Science ®Google Scholar
• Kollias G, Douni E, Kassiotis G, Kontoyiannis D. On the role of TNF and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol Rev 1999; 169: 175–194
   PubMed Web of Science ®Google Scholar
• Jimi E, Ghosh S. Role of nuclear factor-kappaB in the immune system and bone. Immunol Rev 2005; 208: 80–87
   PubMed Web of Science ®Google Scholar
• Abu-Amer Y. Mechanisms of inflammatory mediators in bone loss diseases. Molecular biology in orthopedics, RN Rosier, CH Evans. AAOS, New York 2003; 229–239
   Google Scholar
• Clohisy J, Roy B, Biondo C, Frazier E, Willis D, Teitelbaum S, Abu-Amer Y. Direct inhibition of NF-kB blocks bone erosion associated with inflammatory arthritis. J Immunol 2003; 171: 5547–5553
   PubMed Web of Science ®Google Scholar
• Seetharaman R, Mora AL, Nabozny G, Boothby M, Chen J. Essential role of T cell NF-kB activation in collagen-induced arthritis. J Immunol 1999; 163: 1577–1583
   PubMed Web of Science ®Google Scholar
• DiDonato J, Hayakawa M, Rothwarf D, Zandi E, Karin M. A cytokine-responsive I-kB kinase that activates the transcription factor Nf-kB. Nature 1997; 388: 548–554
   PubMed Web of Science ®Google Scholar
• Mercurio F, Zhu H, Murray B, Bennet B, Li J, Young D, Barbosa M, Mann M. IKK1 and IKK2: Cytokine-activated IkB kinases essential for NF-kB activation. Science 1997; 278: 866–872
   Google Scholar
• Regnier C, Song H, Gao X, Goeddel D, Cao Z, Rothe M. Identification and characterization of an I-kB kinase. Cell 1997; 90: 373–383
   PubMed Web of Science ®Google Scholar
• Stancovski I, Baltimore D. NF-kB activation: The IkB kinase revealed?. Cell 1997; 91: 299–302
   PubMed Web of Science ®Google Scholar
• Li X, Massa PE, Hanidu A, Peet GW, Aro P, Savitt A, Mische S, Li J, Marcu KB. IKK-alpha, IKK-beta, and NEMO/IKK-gamma are each required for the NF-kB-mediated inflammatory response program. J Biol Chem 2002; 277: 45129–45140
   PubMed Web of Science ®Google Scholar
• Li XH, Fang X, Gaynor RB. Role of IKK-gamma /NEMO in assembly of the IkB kinase complex. J Biol Chem 2001; 276: 4494–4500
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Kim DW, Kwak YT, Prajapati S, Verma U, Gaynor RB. IKKgamma/NEMO facilitates the recruitment of the Ikappa B proteins into the Ikappa B kinase complex. J Biol Chem 2001; 276: 36327–36336
   PubMedGoogle Scholar
• Rothwarf D, Zandi E, Natoli G, Karin M. IKK-gamma is an essential regulatory subunit of the IkB kinase complex. Science 1998; 395: 297–300
   Google Scholar
• Makris C, Roberts JL, Karin M. The carboxyl-terminal region of IkB kinase-gamma (IKK-g) is required for full IKK activation. Mol Cell Biol 2002; 22: 6573–6581
   PubMedGoogle Scholar
• May MJ, Marienfeld RB, Ghosh S. Characterization of the Ikappa B-kinase NEMO binding domain. J Biol Chem 2002; 277: 45992–46000
   PubMedGoogle Scholar
• May MJ, D'Acquisto F, Madge LA, Glockner J, Pober JS, Ghosh S. Selective inhibition of NF-kappa B activation by a peptide that blocks the interaction of NEMO with the Ikappa B kinase complex. Science 2000; 289: 1550–1554
   PubMed Web of Science ®Google Scholar
• Tak P, Erlag D, Upperele K, Geest Vd, Verbeek M, Bennet B, Boyle D, Manning A, Firestein G. Inhibitor of nuclear factor [Kappa]B Kinase [beta] is a key regulator of synovial inflammation. Arthritis Rheum 2001; 44: 1897–1907
   PubMed Web of Science ®Google Scholar
• Dai S, Hirayama T, Abbas S, Abu-Amer Y. The IkB Kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J Biol Chem 2004; 279: 37219–37222
   PubMedGoogle Scholar
• Jimi E, Aoki K, Saito H, D'Acquisto F, May MJ, Nakamura I, Sudo T, Kojima T, Okamoto F, Fukushima H, et al. Selective inhibition of NF-B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med 2004; 10: 617–624
   PubMed Web of Science ®Google Scholar
• Tanaka M, Fuentes ME, Yamaguchi K, Durnin MH, Dalrymple SA, Hardy KL, Goeddel DV. Embryonic lethality, liver degeneration, and impaired NF-kappa B activation in IKK-beta-deficient mice. Immunity 1999; 10: 421–429
   PubMed Web of Science ®Google Scholar
• Kaisho T, Takeda K, Tsujimura T, Kawai T, Nomura F, Terada N, Akira S. IkB Kinase-alpha is essential for mature B cell development and function. J Exp Med 2001; 193: 417–426
   PubMedGoogle Scholar
• Ruocco MG, Maeda S, Park JM, Lawrence T, Hsu L-C, Cao Y, Schett G, Wagner EF, Karin M. IkB kinase-beta, but not IKK-alpha, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med 2005; 201: 1677–1687
   PubMed Web of Science ®Google Scholar
• Andreakos E. Targeting cytokines in autoimmunity: New approaches, new promise. Expert Opin Biol Ther 2003; 3: 435–447
   PubMed Web of Science ®Google Scholar
• Izmailova ES, Paz N, Alencar H, Chun M, Schopf L, Hepperle M, Lane JH, Harriman G, Xu Y, Ocain T, et al. Use of molecular imaging to quantify response to IKK-2 inhibitor treatment in murine arthritis. Arthritis Rheum 2007; 56: 117–128
   PubMed Web of Science ®Google Scholar
• Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G, Chen Y, Hu Y, Fong A, Sun SC, et al. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 2001; 293: 1495–1499
   PubMed Web of Science ®Google Scholar
• Chaisson ML, Branstetter DG, Derry JM, Armstrong AP, Tometsko ME, Takeda K, Akira S, Dougall WC. Osteoclast differentiation is impaired in the absence of IkB kinase-alpha. J Biol Chem 2004; 279: 54841–54848
   Google Scholar
• Aya K, Alhawagri M, Hagen-Stapleton A, Kitaura H, Kanagawa O, Novack DV. NF-(kappa)B-inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis. J Clin Invest 2005; 115: 1848–1854
   PubMed Web of Science ®Google Scholar
• Israel A. A regulator branches out. Nature 2003; 423: 596–597
   Google Scholar
• van de Loo FA, van den Berg WB. Gene therapy for rheumatoid arthritis. Lessons from animal models, including studies on interleukin-4, interleukin-10 and interleukin-1 receptor antagonist as potential disease modulators. Rheum Dis Clin North Am 2002; 28: 127–149
   Google Scholar
• Harjacek M, Diaz-Cano S, Alman BA, Coburn J, Ruthazer R, Wolfe H, Steere AC. Prominent expression of mRNA for proinflammatory cytokines in synovium in patients with juvenile rheumatoid arthritis or chronic Lyme arthritis. J Rheumatol 2000; 27: 497–503
   Google Scholar
• Abu-Amer Y. IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kB. J Clin Invest 2001; 107: 1375–1385
   PubMed Web of Science ®Google Scholar
• Hirayama T, Dai S, Abbas S, Yamanaka Y, Abu-Amer Y. Inhibition of inflammatory bone erosion by constitutively active STAT-6 through blockade of JNK and NF-kB activation. Arthritis Rheum 2005; 52: 2719–2729
   Google Scholar
• Takayanagi H, Ogazawara K, Hida S, Chiba T, Murata S, Sato K, Oda H, Tanaka K, Taniguichi T. T-cell-mediated regulation of osteoclastogenesis by signaling cross-talk between RANKL and IFN-γ. Nature 2000; 408: 600–605
   PubMed Web of Science ®Google Scholar
• Straus DS, Pascual G, Li M, Welch JS, Ricote M, Hsiang CH, Sengchanthalangsy LL, Ghosh G, Glass CK. 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci USA 2000; 97: 4844–4849
   PubMed Web of Science ®Google Scholar
• Mbalaviele G, Abu-Amer Y, Meng A, Jaiswal R, Beck S, Pittenger M, Thiede M, Marshak S. Activation of peroxisome proliferator-activated receptor-y pathway inhibits osteoclast differentiation. J Biol Chem 2000; 275: 14388–14393
   PubMed Web of Science ®Google Scholar
• Hoshino K, Sugiyama T, Matsumoto M, Tanaka T, Saito M, Hemmi H, Ohara O, Akira S, Kaisho T. IkappaB kinase-alpha is critical for interferon-alpha production induced by Toll-like receptors 7 and 9. Nature 2006; 440: 949–953
   PubMed Web of Science ®Google Scholar
• Li Q, Lu Q, Bottero V, Estepa G, Morrison L, Mercurio F, Verma IM. Enhanced NF-kB activation and cellular function in macrophages lacking IkB kinase 1 (IKK1). Proc Natl Acad Sci USA 2005; 12425–12430
   Google Scholar
• Lawrence T, Bebien M, Liu GY, Nizet V, Karin M. IKK-alpha- limits macrophage NF-kB activation and contributes to the resolution of inflammation. Nature 2005; 434: 1138–1143
   PubMed Web of Science ®Google Scholar
• Correa RG, Matsui T, Tergaonkar V, Rodriguez-Esteban C, Izpisua-Belmonte JC, Verma IM. Zebrafish IkappaB kinase 1 negatively regulates NF-kappaB activity. Curr Biol 2005; 15: 1291–1295
   Google Scholar